Pfizer Oncology Focusing On Genetic Drivers Of Cancer
This article was originally published in Pharmaceutical Approvals Monthly
Pfizer’s latest refinement to its oncology R&D strategy includes an increased focus on personalized medicine, concentrating on biomarkers for patient selection and development of companion diagnostics.
You may also be interested in...
Failure is the second in two months for Sutent, which is a lynchpin of Pfizer's oncology strategy.
Surprisingly positive data from two early-stage trials in metastatic melanoma with Plexxikon/Roche’s BRAF inhibitor, PLX-4032, and its quick move into Phase III, is garnering attention for the new class of cancer therapy. But there is one troubling sign of toxicity, and other research on the BRAF pathway is prompting debate over the pros and cons of specific versus broad activity.
With a lot of determination and a lot of licensing, Pfizer has managed to pack its oncology pipeline with novel mechanisms. Now the company is trying to innovate its business organization to make the most of what it has